<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20231011203530&amp;utm_source=Chrome&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20231011203530&amp;utm_source=Chrome&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Thu, 12 Oct 2023 00:35:31 +0000</lastbuilddate>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Cardio-Oncology Rehabilitation Programs-The Next Phase in Improving Care for Cancer Survivors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37819675/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 11. doi: 10.1001/jamacardio.2023.3568. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37819675/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37819675</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3568>10.1001/jamacardio.2023.3568</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37819675</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Nausheen Akhter</dc:creator>
<dc:creator>Susan Dent</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Cardio-Oncology Rehabilitation Programs-The Next Phase in Improving Care for Cancer Survivors</dc:title>
<dc:identifier>pmid:37819675</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3568</dc:identifier>
</item>
<item>
<title>Mitochondrial Respiration and Exercise Performance in Patients With Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37819670/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 11. doi: 10.1001/jamacardio.2023.3574. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37819670/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37819670</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3574>10.1001/jamacardio.2023.3574</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37819670</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Johannes Burtscher</dc:creator>
<dc:creator>Martin Burtscher</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Mitochondrial Respiration and Exercise Performance in Patients With Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:37819670</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3574</dc:identifier>
</item>
<item>
<title>Concordance of a High Lipoprotein(a) Concentration Among Relatives</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37819667/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: The findings of this cross-sectional study suggest that the yield of cascade screening of first-degree relatives of individuals with high Lp(a) levels is over 40%. These findings support recent recommendations to use this approach to identify additional individuals at ASCVD risk based on Lp(a) concentrations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 11. doi: 10.1001/jamacardio.2023.3548. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Lipoprotein(a) (Lp[a]) concentrations are a highly heritable and potential causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Recent consensus statements by the European Atherosclerosis Society and American Heart Association recommend screening of relatives of individuals with high Lp(a) concentrations, but the expected yield of this approach has not been quantified in large populations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To measure the prevalence of high Lp(a) concentrations among first- and second-degree relatives of individuals with high Lp(a) concentrations compared with unrelated participants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: In this cross-sectional analysis, pairs of first-degree (n = 19 899) and second-degree (n = 9715) relatives with measured Lp(a) levels from the UK Biobank study and random pairs of unrelated individuals (n = 184 764) were compared. Data for this study were collected from March 2006 to August 2010 and analyzed from December 2021 to August 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Serum Lp(a) levels, with a high Lp(a) level defined as at least 125 nmol/L.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURE: Concordance of clinically relevant high Lp(a) levels in first- and second-degree relatives of index participants with high Lp(a) levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 52 418 participants were included in the analysis (mean [SD] age, 57.3 [8.0] years; 29 825 [56.9%] women). Levels of Lp(a) were correlated among pairs of first-degree (Spearman ρ = 0.45; P &lt; .001) and second-degree (Spearman ρ = 0.22; P &lt; .001) relatives. A total of 1607 of 3420 (47.0% [95% CI, 45.3%-48.7%]) first-degree and 514 of 1614 (31.8% [95% CI, 29.6%-34.2%]) second-degree relatives of index participants with high Lp(a) levels also had elevated concentrations compared with 4974 of 30 258 (16.4% [95% CI, 16.0%-16.9%]) pairs of unrelated individuals. The concordance in high Lp(a) levels was generally consistent among subgroups (eg, those with prior ASCVD, postmenopausal women, and statin users). The odds ratios for relatives to have high Lp(a) levels if their index relative had a high Lp(a) level compared with those whose index relatives did not have high Lp(a) levels were 7.4 (95% CI, 6.8-8.1) for first-degree relatives and 3.0 (95% CI, 2.7-3.4) for second-degree relatives.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: The findings of this cross-sectional study suggest that the yield of cascade screening of first-degree relatives of individuals with high Lp(a) levels is over 40%. These findings support recent recommendations to use this approach to identify additional individuals at ASCVD risk based on Lp(a) concentrations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37819667/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37819667</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3548>10.1001/jamacardio.2023.3548</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37819667</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Laurens F Reeskamp</dc:creator>
<dc:creator>Tycho R Tromp</dc:creator>
<dc:creator>Aniruddh P Patel</dc:creator>
<dc:creator>Shirin Ibrahim</dc:creator>
<dc:creator>Mark Trinder</dc:creator>
<dc:creator>Sara Haidermota</dc:creator>
<dc:creator>G Kees Hovingh</dc:creator>
<dc:creator>Erik S G Stroes</dc:creator>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:creator>Amit V Khera</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Concordance of a High Lipoprotein(a) Concentration Among Relatives</dc:title>
<dc:identifier>pmid:37819667</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3548</dc:identifier>
</item>
<item>
<title>Cardio-Oncology Rehabilitation for Cancer Survivors With High Cardiovascular Risk: A Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37819656/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSION AND RELEVANCE: The CORE trial showed that a cardio-oncology rehabilitation model among cancer survivors with high cardiovascular risk was associated with greater improvements in peak V̇o2 compared with usual care encompassing an exercise intervention in a community setting. The CBCR also showed superior results in exercise adherence, cardiovascular risk factor control, QOL, and health literacy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 11. doi: 10.1001/jamacardio.2023.3558. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Cardiovascular disease is a leading cause of morbidity in cancer survivors, which makes strategies aimed at mitigating cardiovascular risk a subject of major contemporary importance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess whether a center-based cardiac rehabilitation (CBCR) framework compared with usual care encompassing community-based exercise training (CBET) is superior for cardiorespiratory fitness improvement and cardiovascular risk factor control among cancer survivors with high cardiovascular risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This prospective, single-center, randomized clinical trial (CORE trial) included adult cancer survivors who had exposure to cardiotoxic cancer treatment and/or previous cardiovascular disease. Enrollment took place from March 1, 2021, to March 31, 2022. End points were assessed at baseline and after the 8-week intervention.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Participants were randomly assigned in a 1:1 ratio to 8 weeks of CBCR or CBET. The combined aerobic and resistance exercise sessions were performed twice a week.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The powered primary efficacy measure was change in peak oxygen consumption (V̇o2) at 2 months. Secondary outcomes included handgrip maximal strength, functional performance, blood pressure (BP), body composition, body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), lipid profile, plasma biomarker levels, physical activity (PA) levels, psychological distress, quality of life (QOL), and health literacy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 75 participants completed the study (mean [SD] age, 53.6 [12.3] years; 58 [77.3%] female), with 38 in the CBCR group and 37 in the CBET group. Participants in CBCR achieved a greater mean (SD) increase in peak V̇o2 than those in CBET (2.1 [2.8] mL/kg/min vs 0.8 [2.5] mL/kg/min), with a between-group mean difference of 1.3 mL/kg/min (95% CI, 0.1-2.6 mL/kg/min; P = .03). Compared with the CBET group, the CBCR group also attained a greater mean (SD) reduction in systolic BP (-12.3 [11.8] mm Hg vs -1.9 [12.9] mm Hg; P &lt; .001), diastolic BP (-5.0 [5.7] mm Hg vs -0.5 [7.0] mm Hg; P = .003), and BMI (-1.2 [0.9] vs 0.2 [0.7]; P &lt; .001) and greater mean (SD) improvements in PA levels (1035.2 [735.7] metabolic equivalents [METs]/min/wk vs 34.1 [424.4] METs/min/wk; P &lt; .001), QOL (14.0 [10.0] points vs 0.4 [12.9] points; P &lt; .001), and health literacy scores (2.7 [1.6] points vs 0.1 [1.4] points; P &lt; .001). Exercise adherence was significantly higher in the CBCR group than in the CBET group (mean [SD] sessions completed, 90.3% [11.8%] vs 68.4% [22.1%]; P &lt; .001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION AND RELEVANCE: The CORE trial showed that a cardio-oncology rehabilitation model among cancer survivors with high cardiovascular risk was associated with greater improvements in peak V̇o2 compared with usual care encompassing an exercise intervention in a community setting. The CBCR also showed superior results in exercise adherence, cardiovascular risk factor control, QOL, and health literacy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05132998.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37819656/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37819656</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3558>10.1001/jamacardio.2023.3558</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37819656</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Sofia Gonçalves Viamonte</dc:creator>
<dc:creator>Ana Vieira Joaquim</dc:creator>
<dc:creator>Alberto Jorge Alves</dc:creator>
<dc:creator>Eduardo Vilela</dc:creator>
<dc:creator>Andreia Capela</dc:creator>
<dc:creator>Cristina Ferreira</dc:creator>
<dc:creator>Barbara Fresco Duarte</dc:creator>
<dc:creator>Nuno Dias Rato</dc:creator>
<dc:creator>Madalena Pinheiro Teixeira</dc:creator>
<dc:creator>Aida Tavares</dc:creator>
<dc:creator>Mário Santos</dc:creator>
<dc:creator>Fernando Ribeiro</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Cardio-Oncology Rehabilitation for Cancer Survivors With High Cardiovascular Risk: A Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37819656</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3558</dc:identifier>
</item>
<item>
<title>Corrected to Open Access Status</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37819649/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 11. doi: 10.1001/jamacardio.2023.3790. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37819649/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37819649</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3790>10.1001/jamacardio.2023.3790</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37819649</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:date>2023-10-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Corrected to Open Access Status</dc:title>
<dc:identifier>pmid:37819649</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3790</dc:identifier>
</item>
<item>
<title>Mitochondrial Respiration and Exercise Performance in Patients With Heart Failure With Preserved Ejection Fraction-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37819648/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 11. doi: 10.1001/jamacardio.2023.3577. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37819648/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37819648</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3577>10.1001/jamacardio.2023.3577</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37819648</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Anthony J A Molina</dc:creator>
<dc:creator>Erich Gnaiger</dc:creator>
<dc:creator>Dalane W Kitzman</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Mitochondrial Respiration and Exercise Performance in Patients With Heart Failure With Preserved Ejection Fraction-Reply</dc:title>
<dc:identifier>pmid:37819648</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3577</dc:identifier>
</item>
<item>
<title>Mitochondrial Respiration and Exercise Performance in Patients With Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37819645/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 11. doi: 10.1001/jamacardio.2023.3571. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37819645/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37819645</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3571>10.1001/jamacardio.2023.3571</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37819645</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Huda Abu-Own</dc:creator>
<dc:creator>Olaf Wendler</dc:creator>
<dc:creator>Darlington O Okonko</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Mitochondrial Respiration and Exercise Performance in Patients With Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:37819645</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3571</dc:identifier>
</item>
<item>
<title>Errors in Table and Results Section</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37819385/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 1;8(10):1000. doi: 10.1001/jamacardio.2023.3773.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37819385/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37819385</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3773>10.1001/jamacardio.2023.3773</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37819385</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:date>2023-10-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Errors in Table and Results Section</dc:title>
<dc:identifier>pmid:37819385</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3773</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37819384/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 1;8(10):896. doi: 10.1001/jamacardio.2022.3456.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37819384/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37819384</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2022.3456>10.1001/jamacardio.2022.3456</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37819384</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:date>2023-10-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:37819384</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2022.3456</dc:identifier>
</item>
<item>
<title>MRP1-Dependent Extracellular Release of Glutathione Induces Cardiomyocyte Ferroptosis After Ischemia-Reperfusion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37818671/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Glutathione was released continuously during IR, primarily in an MRP1-dependent manner, and induced ferroptosis. Suppression of glutathione release attenuated ferroptosis and reduced myocardial infarct size following IR.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Oct 11. doi: 10.1161/CIRCRESAHA.123.323517. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The membrane components of cardiomyocytes are rich in polyunsaturated fatty acids, which are easily oxidized. Thus, an efficient glutathione-based lipid redox system is essential for maintaining cellular functions. However, the relationship between disruption of the redox system during ischemia-reperfusion (IR), oxidized lipid production, and consequent cell death (ferroptosis) remains unclear. We investigated the mechanisms underlying the disruption of the glutathione-mediated reduction system related to ferroptosis during IR and developed intervention strategies to suppress ferroptosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In vivo fluctuations of both intra- and extracellular metabolite levels during IR were explored via microdialysis and tissue metabolome analysis. Oxidized phosphatidylcholines were assessed using liquid chromatography high-resolution mass spectrometry. The areas at risk following IR were assessed using triphenyl-tetrazolium chloride/Evans blue stain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Metabolomic analysis combined with microdialysis revealed a significant release of glutathione from the ischemic region into extracellular spaces during ischemia and after reperfusion. The release of glutathione into extracellular spaces and a concomitant decrease in intracellular glutathione concentrations were also observed during anoxia-reperfusion in an in vitro cardiomyocyte model. This extracellular glutathione release was prevented by chemical inhibition or genetic suppression of glutathione transporters, mainly MRP1 (multidrug resistance protein 1). Treatment with MRP1 inhibitor reduced the intracellular reactive oxygen species levels and lipid peroxidation, thereby inhibiting cell death. Subsequent in vivo evaluation of endogenously oxidized phospholipids following IR demonstrated the involvement of ferroptosis, as levels of multiple oxidized phosphatidylcholines were significantly elevated in the ischemic region 12 hours after reperfusion. Inhibition of the MRP1 transporter also alleviated intracellular glutathione depletion in vivo and significantly reduced the generation of oxidized phosphatidylcholines. Administration of MRP1 inhibitors significantly attenuated infarct size after IR injury.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Glutathione was released continuously during IR, primarily in an MRP1-dependent manner, and induced ferroptosis. Suppression of glutathione release attenuated ferroptosis and reduced myocardial infarct size following IR.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37818671/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37818671</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323517>10.1161/CIRCRESAHA.123.323517</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37818671</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Genki Ichihara</dc:creator>
<dc:creator>Yoshinori Katsumata</dc:creator>
<dc:creator>Yuki Sugiura</dc:creator>
<dc:creator>Yuta Matsuoka</dc:creator>
<dc:creator>Rae Maeda</dc:creator>
<dc:creator>Jin Endo</dc:creator>
<dc:creator>Atsushi Anzai</dc:creator>
<dc:creator>Kohsuke Shirakawa</dc:creator>
<dc:creator>Hidenori Moriyama</dc:creator>
<dc:creator>Hiroki Kitakata</dc:creator>
<dc:creator>Takahiro Hiraide</dc:creator>
<dc:creator>Shinichi Goto</dc:creator>
<dc:creator>Seien Ko</dc:creator>
<dc:creator>Yuji Iwasawa</dc:creator>
<dc:creator>Kazuhisa Sugai</dc:creator>
<dc:creator>Kyohei Daigo</dc:creator>
<dc:creator>Shinya Goto</dc:creator>
<dc:creator>Kazuki Sato</dc:creator>
<dc:creator>Kenichi Yamada</dc:creator>
<dc:creator>Makoto Suematsu</dc:creator>
<dc:creator>Masaki Ieda</dc:creator>
<dc:creator>Motoaki Sano</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>MRP1-Dependent Extracellular Release of Glutathione Induces Cardiomyocyte Ferroptosis After Ischemia-Reperfusion</dc:title>
<dc:identifier>pmid:37818671</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323517</dc:identifier>
</item>
<item>
<title>Body Mass Index, Adverse Pregnancy Outcomes, and Cardiovascular Disease Risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37814889/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: There was heterogeneity across APO subtypes in their association with postpartum CVD risk factors and mediation of the association between early pregnancy obesity and postpartum CVD risk factors. However, only a small or nonsignificant proportion of the association between obesity and CVD risk factors was mediated by any of the APOs, suggesting APOs are a marker of prepregnancy CVD risk and not a predominant cause of postpartum CVD risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Oct 10. doi: 10.1161/CIRCRESAHA.123.322762. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Obesity is a well-established risk factor for both adverse pregnancy outcomes (APOs) and cardiovascular disease (CVD). However, it is not known whether APOs are mediators or markers of the obesity-CVD relationship. This study examined the association between body mass index, APOs, and postpartum CVD risk factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The sample included adults from the nuMoM2b (Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-To-Be) Heart Health Study who were enrolled in their first trimester (6 weeks-13 weeks 6 days gestation) from 8 US sites. Participants had a follow-up visit at 3.7 years postpartum. APOs, which included hypertensive disorders of pregnancy, preterm birth, small-for-gestational-age birth, and gestational diabetes, were centrally adjudicated. Mediation analyses estimated the association between early pregnancy body mass index and postpartum CVD risk factors (hypertension, hyperlipidemia, and diabetes) and the proportion mediated by each APO adjusted for demographics and baseline health behaviors, psychosocial stressors, and CVD risk factor levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 4216 participants enrolled, mean±SD maternal age was 27±6 years. Early pregnancy prevalence of overweight was 25%, and obesity was 22%. Hypertensive disorders of pregnancy occurred in 15%, preterm birth in 8%, small-for-gestational-age birth in 11%, and gestational diabetes in 4%. Early pregnancy obesity, compared with normal body mass index, was associated with significantly higher incidence of postpartum hypertension (adjusted odds ratio, 1.14 [95% CI, 1.10-1.18]), hyperlipidemia (1.11 [95% CI, 1.08-1.14]), and diabetes (1.03 [95% CI, 1.01-1.04]) even after adjustment for baseline CVD risk factor levels. APOs were associated with higher incidence of postpartum hypertension (1.97 [95% CI, 1.61-2.40]) and hyperlipidemia (1.31 [95% CI, 1.03-1.67]). Hypertensive disorders of pregnancy mediated a small proportion of the association between obesity and incident hypertension (13% [11%-15%]) and did not mediate associations with incident hyperlipidemia or diabetes. There was no significant mediation by preterm birth or small-for-gestational-age birth.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: There was heterogeneity across APO subtypes in their association with postpartum CVD risk factors and mediation of the association between early pregnancy obesity and postpartum CVD risk factors. However, only a small or nonsignificant proportion of the association between obesity and CVD risk factors was mediated by any of the APOs, suggesting APOs are a marker of prepregnancy CVD risk and not a predominant cause of postpartum CVD risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37814889/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37814889</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322762>10.1161/CIRCRESAHA.123.322762</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37814889</guid>
<pubDate>Tue, 10 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Lucia C Petito</dc:creator>
<dc:creator>Xiaoning Huang</dc:creator>
<dc:creator>Katharine Harrington</dc:creator>
<dc:creator>Rebecca B McNeil</dc:creator>
<dc:creator>Natalie A Bello</dc:creator>
<dc:creator>C N Bairey Merz</dc:creator>
<dc:creator>Eliza C Miller</dc:creator>
<dc:creator>Rupa Ravi</dc:creator>
<dc:creator>Christina Scifres</dc:creator>
<dc:creator>Janet Catov</dc:creator>
<dc:creator>Victoria Pemberton</dc:creator>
<dc:creator>Jasmina Varagic</dc:creator>
<dc:creator>Phyllis C Zee</dc:creator>
<dc:creator>Lynn M Yee</dc:creator>
<dc:creator>Mitali Ray</dc:creator>
<dc:creator>Jin Kyung Kim</dc:creator>
<dc:creator>Abbi Lane-Cordova</dc:creator>
<dc:creator>Jennifer Lewey</dc:creator>
<dc:creator>Lauren H Theilen</dc:creator>
<dc:creator>George R Saade</dc:creator>
<dc:creator>Philip Greenland</dc:creator>
<dc:creator>William A Grobman</dc:creator>
<dc:creator>NICHD nuMoM2b and NHLBI nuMoM2b Heart Health Study Networks</dc:creator>
<dc:date>2023-10-10</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Body Mass Index, Adverse Pregnancy Outcomes, and Cardiovascular Disease Risk</dc:title>
<dc:identifier>pmid:37814889</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322762</dc:identifier>
</item>
<item>
<title>Cardiac Troponins for Diagnosis and Prognostic Assessment of Immune Checkpoint Inhibitor Myocarditis and Myositis: The Emerging Importance of Peripheral Vision</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37812655/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 10;148(15):1135-1137. doi: 10.1161/CIRCULATIONAHA.123.065988. Epub 2023 Oct 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37812655/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37812655</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065988>10.1161/CIRCULATIONAHA.123.065988</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37812655</guid>
<pubDate>Mon, 09 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Christopher deFilippi</dc:creator>
<dc:creator>Ana Barac</dc:creator>
<dc:date>2023-10-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiac Troponins for Diagnosis and Prognostic Assessment of Immune Checkpoint Inhibitor Myocarditis and Myositis: The Emerging Importance of Peripheral Vision</dc:title>
<dc:identifier>pmid:37812655</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065988</dc:identifier>
</item>
<item>
<title>Letter by Krisai et al Regarding Article, "Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37812654/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 10;148(15):1182. doi: 10.1161/CIRCULATIONAHA.123.065076. Epub 2023 Oct 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37812654/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37812654</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065076>10.1161/CIRCULATIONAHA.123.065076</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37812654</guid>
<pubDate>Mon, 09 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Philipp Krisai</dc:creator>
<dc:creator>Michael Kühne</dc:creator>
<dc:creator>Christian Sticherling</dc:creator>
<dc:date>2023-10-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Krisai et al Regarding Article, "Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial"</dc:title>
<dc:identifier>pmid:37812654</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065076</dc:identifier>
</item>
<item>
<title>Implantable Cardioverter Defibrillator in Patients With Nonischemic Systolic Heart Failure With and Without Cardiac Resynchronization Therapy: Extended Follow-Up Study of the DANISH Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37812653/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 10;148(15):1179-1181. doi: 10.1161/CIRCULATIONAHA.123.065560. Epub 2023 Oct 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37812653/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37812653</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065560>10.1161/CIRCULATIONAHA.123.065560</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37812653</guid>
<pubDate>Mon, 09 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Jawad H Butt</dc:creator>
<dc:creator>Adelina Yafasova</dc:creator>
<dc:creator>Seiko N Doi</dc:creator>
<dc:creator>Jens C Nielsen</dc:creator>
<dc:creator>Jens Haarbo</dc:creator>
<dc:creator>Hans Eiskjær</dc:creator>
<dc:creator>Axel Brandes</dc:creator>
<dc:creator>Anna M Thøgersen</dc:creator>
<dc:creator>Finn Gustafsson</dc:creator>
<dc:creator>Christian Hassager</dc:creator>
<dc:creator>Jesper H Svendsen</dc:creator>
<dc:creator>Dan E Høfsten</dc:creator>
<dc:creator>Lars Videbæk</dc:creator>
<dc:creator>Christian Torp-Pedersen</dc:creator>
<dc:creator>Steen Pehrson</dc:creator>
<dc:creator>Jens Jakob Thune</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:date>2023-10-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Implantable Cardioverter Defibrillator in Patients With Nonischemic Systolic Heart Failure With and Without Cardiac Resynchronization Therapy: Extended Follow-Up Study of the DANISH Trial</dc:title>
<dc:identifier>pmid:37812653</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065560</dc:identifier>
</item>
<item>
<title>Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37807924/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>Cardiovascular-kidney-metabolic health reflects the interplay among metabolic risk factors, chronic kidney disease, and the cardiovascular system and has profound impacts on morbidity and mortality. There are multisystem consequences of poor cardiovascular-kidney-metabolic health, with the most significant clinical impact being the high associated incidence of cardiovascular disease events and cardiovascular mortality. There is a high prevalence of poor cardiovascular-kidney-metabolic health in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 9. doi: 10.1161/CIR.0000000000001184. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiovascular-kidney-metabolic health reflects the interplay among metabolic risk factors, chronic kidney disease, and the cardiovascular system and has profound impacts on morbidity and mortality. There are multisystem consequences of poor cardiovascular-kidney-metabolic health, with the most significant clinical impact being the high associated incidence of cardiovascular disease events and cardiovascular mortality. There is a high prevalence of poor cardiovascular-kidney-metabolic health in the population, with a disproportionate burden seen among those with adverse social determinants of health. However, there is also a growing number of therapeutic options that favorably affect metabolic risk factors, kidney function, or both that also have cardioprotective effects. To improve cardiovascular-kidney-metabolic health and related outcomes in the population, there is a critical need for (1) more clarity on the definition of cardiovascular-kidney-metabolic syndrome; (2) an approach to cardiovascular-kidney-metabolic staging that promotes prevention across the life course; (3) prediction algorithms that include the exposures and outcomes most relevant to cardiovascular-kidney-metabolic health; and (4) strategies for the prevention and management of cardiovascular disease in relation to cardiovascular-kidney-metabolic health that reflect harmonization across major subspecialty guidelines and emerging scientific evidence. It is also critical to incorporate considerations of social determinants of health into care models for cardiovascular-kidney-metabolic syndrome and to reduce care fragmentation by facilitating approaches for patient-centered interdisciplinary care. This presidential advisory provides guidance on the definition, staging, prediction paradigms, and holistic approaches to care for patients with cardiovascular-kidney-metabolic syndrome and details a multicomponent vision for effectively and equitably enhancing cardiovascular-kidney-metabolic health in the population.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37807924/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37807924</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001184>10.1161/CIR.0000000000001184</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37807924</guid>
<pubDate>Mon, 09 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Chiadi E Ndumele</dc:creator>
<dc:creator>Janani Rangaswami</dc:creator>
<dc:creator>Sheryl L Chow</dc:creator>
<dc:creator>Ian J Neeland</dc:creator>
<dc:creator>Katherine R Tuttle</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Josef Coresh</dc:creator>
<dc:creator>Roy O Mathew</dc:creator>
<dc:creator>Carissa M Baker-Smith</dc:creator>
<dc:creator>Mercedes R Carnethon</dc:creator>
<dc:creator>Jean-Pierre Despres</dc:creator>
<dc:creator>Jennifer E Ho</dc:creator>
<dc:creator>Joshua J Joseph</dc:creator>
<dc:creator>Walter N Kernan</dc:creator>
<dc:creator>Amit Khera</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>Carolyn L Lekavich</dc:creator>
<dc:creator>Eldrin F Lewis</dc:creator>
<dc:creator>Kevin B Lo</dc:creator>
<dc:creator>Bige Ozkan</dc:creator>
<dc:creator>Latha P Palaniappan</dc:creator>
<dc:creator>Sonali S Patel</dc:creator>
<dc:creator>Michael J Pencina</dc:creator>
<dc:creator>Tiffany M Powell-Wiley</dc:creator>
<dc:creator>Laurence S Sperling</dc:creator>
<dc:creator>Salim S Virani</dc:creator>
<dc:creator>Jackson T Wright</dc:creator>
<dc:creator>Radhika Rajgopal Singh</dc:creator>
<dc:creator>Mitchell S V Elkind</dc:creator>
<dc:creator>American Heart Association</dc:creator>
<dc:date>2023-10-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association</dc:title>
<dc:identifier>pmid:37807924</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001184</dc:identifier>
</item>
<item>
<title>A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37807920/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led to the conceptualization of cardiovascular-kidney-metabolic syndrome. The confluence of metabolic risk factors and chronic kidney disease within cardiovascular-kidney-metabolic syndrome is strongly linked to risk for adverse cardiovascular and kidney outcomes. In addition, there are unique management considerations...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 9. doi: 10.1161/CIR.0000000000001186. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led to the conceptualization of cardiovascular-kidney-metabolic syndrome. The confluence of metabolic risk factors and chronic kidney disease within cardiovascular-kidney-metabolic syndrome is strongly linked to risk for adverse cardiovascular and kidney outcomes. In addition, there are unique management considerations for individuals with established cardiovascular disease and coexisting metabolic risk factors, chronic kidney disease, or both. An extensive body of literature supports our scientific understanding of, and approach to, prevention and management for individuals with cardiovascular-kidney-metabolic syndrome. However, there are critical gaps in knowledge related to cardiovascular-kidney-metabolic syndrome in terms of mechanisms of disease development, heterogeneity within clinical phenotypes, interplay between social determinants of health and biological risk factors, and accurate assessments of disease incidence in the context of competing risks. There are also key limitations in the data supporting the clinical care for cardiovascular-kidney-metabolic syndrome, particularly in terms of early-life prevention, screening for risk factors, interdisciplinary care models, optimal strategies for supporting lifestyle modification and weight loss, targeting of emerging cardioprotective and kidney-protective therapies, management of patients with both cardiovascular disease and chronic kidney disease, and the impact of systematically assessing and addressing social determinants of health. This scientific statement uses a crosswalk of major guidelines, in addition to a review of the scientific literature, to summarize the evidence and fundamental gaps related to the science, screening, prevention, and management of cardiovascular-kidney-metabolic syndrome.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37807920/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37807920</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001186>10.1161/CIR.0000000000001186</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37807920</guid>
<pubDate>Mon, 09 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Chiadi E Ndumele</dc:creator>
<dc:creator>Ian J Neeland</dc:creator>
<dc:creator>Katherine R Tuttle</dc:creator>
<dc:creator>Sheryl L Chow</dc:creator>
<dc:creator>Roy O Mathew</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Josef Coresh</dc:creator>
<dc:creator>Carissa M Baker-Smith</dc:creator>
<dc:creator>Mercedes R Carnethon</dc:creator>
<dc:creator>Jean-Pierre Després</dc:creator>
<dc:creator>Jennifer E Ho</dc:creator>
<dc:creator>Joshua J Joseph</dc:creator>
<dc:creator>Walter N Kernan</dc:creator>
<dc:creator>Amit Khera</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>Carolyn L Lekavich</dc:creator>
<dc:creator>Eldrin F Lewis</dc:creator>
<dc:creator>Kevin B Lo</dc:creator>
<dc:creator>Bige Ozkan</dc:creator>
<dc:creator>Latha P Palaniappan</dc:creator>
<dc:creator>Sonali S Patel</dc:creator>
<dc:creator>Michael J Pencina</dc:creator>
<dc:creator>Tiffany M Powell-Wiley</dc:creator>
<dc:creator>Laurence S Sperling</dc:creator>
<dc:creator>Salim S Virani</dc:creator>
<dc:creator>Jackson T Wright</dc:creator>
<dc:creator>Radhika Rajgopal Singh</dc:creator>
<dc:creator>Mitchell S V Elkind</dc:creator>
<dc:creator>Janani Rangaswami</dc:creator>
<dc:creator>American Heart Association</dc:creator>
<dc:date>2023-10-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:37807920</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001186</dc:identifier>
</item>
<item>
<title>Antagonistic RALF peptides control an intergeneric hybridization barrier on Brassicaceae stigmas</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37806310/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>Pollen-pistil interactions establish interspecific/intergeneric pre-zygotic hybridization barriers in plants. The rejection of undesired pollen at the stigma is crucial to avoid outcrossing but can be overcome with the support of mentor pollen. The mechanisms underlying this hybridization barrier are largely unknown. Here, in Arabidopsis, we demonstrate that receptor-like kinases FERONIA/CURVY1/ANJEA/HERCULES RECEPTOR KINASE 1 and cell wall proteins LRX3/4/5 interact on papilla cell surfaces...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Oct 7:S0092-8674(23)00981-9. doi: 10.1016/j.cell.2023.09.003. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Pollen-pistil interactions establish interspecific/intergeneric pre-zygotic hybridization barriers in plants. The rejection of undesired pollen at the stigma is crucial to avoid outcrossing but can be overcome with the support of mentor pollen. The mechanisms underlying this hybridization barrier are largely unknown. Here, in Arabidopsis, we demonstrate that receptor-like kinases FERONIA/CURVY1/ANJEA/HERCULES RECEPTOR KINASE 1 and cell wall proteins LRX3/4/5 interact on papilla cell surfaces with autocrine stigmatic RALF1/22/23/33 peptide ligands (sRALFs) to establish a lock that blocks the penetration of undesired pollen tubes. Compatible pollen-derived RALF10/11/12/13/25/26/30 peptides (pRALFs) act as a key, outcompeting sRALFs and enabling pollen tube penetration. By treating Arabidopsis stigmas with synthetic pRALFs, we unlock the barrier, facilitating pollen tube penetration from distantly related Brassicaceae species and resulting in interspecific/intergeneric hybrid embryo formation. Therefore, we uncover a "lock-and-key" system governing the hybridization breadth of interspecific/intergeneric crosses in Brassicaceae. Manipulating this system holds promise for facilitating broad hybridization in crops.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37806310/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37806310</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.09.003>10.1016/j.cell.2023.09.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37806310</guid>
<pubDate>Sun, 08 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Zijun Lan</dc:creator>
<dc:creator>Zihan Song</dc:creator>
<dc:creator>Zhijuan Wang</dc:creator>
<dc:creator>Ling Li</dc:creator>
<dc:creator>Yiqun Liu</dc:creator>
<dc:creator>Shuaihua Zhi</dc:creator>
<dc:creator>Ruihan Wang</dc:creator>
<dc:creator>Jizong Wang</dc:creator>
<dc:creator>Qiyun Li</dc:creator>
<dc:creator>Andrea Bleckmann</dc:creator>
<dc:creator>Li Zhang</dc:creator>
<dc:creator>Thomas Dresselhaus</dc:creator>
<dc:creator>Juan Dong</dc:creator>
<dc:creator>Hongya Gu</dc:creator>
<dc:creator>Sheng Zhong</dc:creator>
<dc:creator>Li-Jia Qu</dc:creator>
<dc:date>2023-10-08</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Antagonistic RALF peptides control an intergeneric hybridization barrier on Brassicaceae stigmas</dc:title>
<dc:identifier>pmid:37806310</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.09.003</dc:identifier>
</item>
<item>
<title>Generative replay underlies compositional inference in the hippocampal-prefrontal circuit</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37804832/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>Human reasoning depends on reusing pieces of information by putting them together in new ways. However, very little is known about how compositional computation is implemented in the brain. Here, we ask participants to solve a series of problems that each require constructing a whole from a set of elements. With fMRI, we find that representations of novel constructed objects in the frontal cortex and hippocampus are relational and compositional. With MEG, we find that replay assembles elements...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 30:S0092-8674(23)01025-5. doi: 10.1016/j.cell.2023.09.004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Human reasoning depends on reusing pieces of information by putting them together in new ways. However, very little is known about how compositional computation is implemented in the brain. Here, we ask participants to solve a series of problems that each require constructing a whole from a set of elements. With fMRI, we find that representations of novel constructed objects in the frontal cortex and hippocampus are relational and compositional. With MEG, we find that replay assembles elements into compounds, with each replay sequence constituting a hypothesis about a possible configuration of elements. The content of sequences evolves as participants solve each puzzle, progressing from predictable to uncertain elements and gradually converging on the correct configuration. Together, these results suggest a computational bridge between apparently distinct functions of hippocampal-prefrontal circuitry and a role for generative replay in compositional inference and hypothesis testing.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37804832/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37804832</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.09.004>10.1016/j.cell.2023.09.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37804832</guid>
<pubDate>Sat, 07 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Philipp Schwartenbeck</dc:creator>
<dc:creator>Alon Baram</dc:creator>
<dc:creator>Yunzhe Liu</dc:creator>
<dc:creator>Shirley Mark</dc:creator>
<dc:creator>Timothy Muller</dc:creator>
<dc:creator>Raymond Dolan</dc:creator>
<dc:creator>Matthew Botvinick</dc:creator>
<dc:creator>Zeb Kurth-Nelson</dc:creator>
<dc:creator>Timothy Behrens</dc:creator>
<dc:date>2023-10-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Generative replay underlies compositional inference in the hippocampal-prefrontal circuit</dc:title>
<dc:identifier>pmid:37804832</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.09.004</dc:identifier>
</item>
<item>
<title>Vertebrate-class-specific binding modes of the alphavirus receptor MXRA8</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37804831/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>MXRA8 is a receptor for chikungunya (CHIKV) and other arthritogenic alphaviruses with mammalian hosts. However, mammalian MXRA8 does not bind to alphaviruses that infect humans and have avian reservoirs. Here, we show that avian, but not mammalian, MXRA8 can act as a receptor for Sindbis, western equine encephalitis (WEEV), and related alphaviruses with avian reservoirs. Structural analysis of duck MXRA8 complexed with WEEV reveals an inverted binding mode compared with mammalian MXRA8 bound to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Oct 2:S0092-8674(23)01029-2. doi: 10.1016/j.cell.2023.09.007. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MXRA8 is a receptor for chikungunya (CHIKV) and other arthritogenic alphaviruses with mammalian hosts. However, mammalian MXRA8 does not bind to alphaviruses that infect humans and have avian reservoirs. Here, we show that avian, but not mammalian, MXRA8 can act as a receptor for Sindbis, western equine encephalitis (WEEV), and related alphaviruses with avian reservoirs. Structural analysis of duck MXRA8 complexed with WEEV reveals an inverted binding mode compared with mammalian MXRA8 bound to CHIKV. Whereas both domains of mammalian MXRA8 bind CHIKV E1 and E2, only domain 1 of avian MXRA8 engages WEEV E1, and no appreciable contacts are made with WEEV E2. Using these results, we generated a chimeric avian-mammalian MXRA8 decoy-receptor that neutralizes infection of multiple alphaviruses from distinct antigenic groups in vitro and in vivo. Thus, different alphaviruses can bind MXRA8 encoded by different vertebrate classes with distinct engagement modes, which enables development of broad-spectrum inhibitors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37804831/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37804831</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.09.007>10.1016/j.cell.2023.09.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37804831</guid>
<pubDate>Sat, 07 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Ofer Zimmerman</dc:creator>
<dc:creator>Maxwell I Zimmerman</dc:creator>
<dc:creator>Saravanan Raju</dc:creator>
<dc:creator>Christopher A Nelson</dc:creator>
<dc:creator>John M Errico</dc:creator>
<dc:creator>Emily A Madden</dc:creator>
<dc:creator>Autumn C Holmes</dc:creator>
<dc:creator>Ahmed O Hassan</dc:creator>
<dc:creator>Laura A VanBlargan</dc:creator>
<dc:creator>Arthur S Kim</dc:creator>
<dc:creator>Lucas J Adams</dc:creator>
<dc:creator>Katherine Basore</dc:creator>
<dc:creator>Bradley M Whitener</dc:creator>
<dc:creator>Sathvik Palakurty</dc:creator>
<dc:creator>Hannah G Davis-Adams</dc:creator>
<dc:creator>Chengqun Sun</dc:creator>
<dc:creator>Theron Gilliland</dc:creator>
<dc:creator>James T Earnest</dc:creator>
<dc:creator>Hongming Ma</dc:creator>
<dc:creator>Gregory D Ebel</dc:creator>
<dc:creator>Christian Zmasek</dc:creator>
<dc:creator>Richard H Scheuermann</dc:creator>
<dc:creator>William B Klimstra</dc:creator>
<dc:creator>Daved H Fremont</dc:creator>
<dc:creator>Michael S Diamond</dc:creator>
<dc:date>2023-10-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Vertebrate-class-specific binding modes of the alphavirus receptor MXRA8</dc:title>
<dc:identifier>pmid:37804831</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.09.007</dc:identifier>
</item>
<item>
<title>Arginine reprograms metabolism in liver cancer via RBM39</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37804830/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>Metabolic reprogramming is a hallmark of cancer. However, mechanisms underlying metabolic reprogramming and how altered metabolism in turn enhances tumorigenicity are poorly understood. Here, we report that arginine levels are elevated in murine and patient hepatocellular carcinoma (HCC), despite reduced expression of arginine synthesis genes. Tumor cells accumulate high levels of arginine due to increased uptake and reduced arginine-to-polyamine conversion. Importantly, the high levels of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 26:S0092-8674(23)01032-2. doi: 10.1016/j.cell.2023.09.011. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Metabolic reprogramming is a hallmark of cancer. However, mechanisms underlying metabolic reprogramming and how altered metabolism in turn enhances tumorigenicity are poorly understood. Here, we report that arginine levels are elevated in murine and patient hepatocellular carcinoma (HCC), despite reduced expression of arginine synthesis genes. Tumor cells accumulate high levels of arginine due to increased uptake and reduced arginine-to-polyamine conversion. Importantly, the high levels of arginine promote tumor formation via further metabolic reprogramming, including changes in glucose, amino acid, nucleotide, and fatty acid metabolism. Mechanistically, arginine binds RNA-binding motif protein 39 (RBM39) to control expression of metabolic genes. RBM39-mediated upregulation of asparagine synthesis leads to enhanced arginine uptake, creating a positive feedback loop to sustain high arginine levels and oncogenic metabolism. Thus, arginine is a second messenger-like molecule that reprograms metabolism to promote tumor growth.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37804830/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37804830</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.09.011>10.1016/j.cell.2023.09.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37804830</guid>
<pubDate>Sat, 07 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Dirk Mossmann</dc:creator>
<dc:creator>Christoph Müller</dc:creator>
<dc:creator>Sujin Park</dc:creator>
<dc:creator>Brendan Ryback</dc:creator>
<dc:creator>Marco Colombi</dc:creator>
<dc:creator>Nathalie Ritter</dc:creator>
<dc:creator>Diana Weißenberger</dc:creator>
<dc:creator>Eva Dazert</dc:creator>
<dc:creator>Mairene Coto-Llerena</dc:creator>
<dc:creator>Sandro Nuciforo</dc:creator>
<dc:creator>Lauriane Blukacz</dc:creator>
<dc:creator>Caner Ercan</dc:creator>
<dc:creator>Veronica Jimenez</dc:creator>
<dc:creator>Salvatore Piscuoglio</dc:creator>
<dc:creator>Fatima Bosch</dc:creator>
<dc:creator>Luigi M Terracciano</dc:creator>
<dc:creator>Uwe Sauer</dc:creator>
<dc:creator>Markus H Heim</dc:creator>
<dc:creator>Michael N Hall</dc:creator>
<dc:date>2023-10-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Arginine reprograms metabolism in liver cancer via RBM39</dc:title>
<dc:identifier>pmid:37804830</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.09.011</dc:identifier>
</item>
<item>
<title>Tricuspid Valve Academic Research Consortium Definitions for Tricuspid Regurgitation and Trial Endpoints</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37804294/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231011203530&amp;v=2.17.9.post6+86293ac
      <description>Interest in the pathophysiology, etiology, management, and outcomes of patients with tricuspid regurgitation (TR) has grown in the wake of multiple natural history studies showing progressively worse outcomes associated with increasing TR severity, even after adjusting for multiple comorbidities. Historically, isolated tricuspid valve surgery has been associated with high in-hospital mortality rates, leading to the development of transcatheter treatment options. The aim of this first Tricuspid...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 28:S0735-1097(23)06403-3. doi: 10.1016/j.jacc.2023.08.008. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Interest in the pathophysiology, etiology, management, and outcomes of patients with tricuspid regurgitation (TR) has grown in the wake of multiple natural history studies showing progressively worse outcomes associated with increasing TR severity, even after adjusting for multiple comorbidities. Historically, isolated tricuspid valve surgery has been associated with high in-hospital mortality rates, leading to the development of transcatheter treatment options. The aim of this first Tricuspid Valve Academic Research Consortium document is to standardize definitions of disease etiology and severity, as well as endpoints for trials that aim to address the gaps in our knowledge related to identification and management of patients with TR. Standardizing endpoints for trials should provide consistency and enable meaningful comparisons between clinical trials. A second Tricuspid Valve Academic Research Consortium document will focus on further defining trial endpoints and will discuss trial design options.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37804294/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231011203530&v=2.17.9.post6+86293ac">37804294</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.008>10.1016/j.jacc.2023.08.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37804294</guid>
<pubDate>Sat, 07 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>Matthew K Lawlor</dc:creator>
<dc:creator>Charles J Davidson</dc:creator>
<dc:creator>Vinay Badhwar</dc:creator>
<dc:creator>Anna Sannino</dc:creator>
<dc:creator>Ernest Spitzer</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Brian R Lindman</dc:creator>
<dc:creator>Yan Topilsky</dc:creator>
<dc:creator>Suzanne J Baron</dc:creator>
<dc:creator>Scott Chadderdon</dc:creator>
<dc:creator>Omar K Khalique</dc:creator>
<dc:creator>Gilbert H L Tang</dc:creator>
<dc:creator>Maurizio Taramasso</dc:creator>
<dc:creator>Paul A Grayburn</dc:creator>
<dc:creator>Luigi Badano</dc:creator>
<dc:creator>Jonathon Leipsic</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Sreekanth Vemulapalli</dc:creator>
<dc:creator>Bjorn Redfors</dc:creator>
<dc:creator>Maria C Alu</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>Josep Rodés-Cabau</dc:creator>
<dc:creator>Gorav Ailawadi</dc:creator>
<dc:creator>Michael Mack</dc:creator>
<dc:creator>Ori Ben-Yehuda</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Jörg Hausleiter</dc:creator>
<dc:creator>TVARC Steering Committee</dc:creator>
<dc:date>2023-10-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Tricuspid Valve Academic Research Consortium Definitions for Tricuspid Regurgitation and Trial Endpoints</dc:title>
<dc:identifier>pmid:37804294</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.008</dc:identifier>
</item>





























</channel>
</rss>